| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/IMT.10.30 |
| P698 | PubMed publication ID | 20636009 |
| P50 | author | Martin F. Bachmann | Q75986419 |
| P2093 | author name string | Alexander Link | |
| P2860 | cites work | Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice | Q48404833 |
| Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. | Q51001680 | ||
| Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus. | Q51776263 | ||
| Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation | Q56798234 | ||
| The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance | Q56904539 | ||
| Immunotherapy for Alzheimer's disease | Q57419087 | ||
| Steady-state dendritic cells expressing cognate antigen terminate memory CD8+ T-cell responses | Q57667259 | ||
| Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice | Q59055762 | ||
| Cancer immunotherapy: moving beyond current vaccines | Q24548229 | ||
| The biological functions of T helper 17 cell effector cytokines in inflammation | Q24614431 | ||
| Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. | Q24655516 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity | Q28257857 | ||
| B-cell tolerance checkpoints in health and autoimmunity | Q28296605 | ||
| Tolerogenic dendritic cells | Q29618755 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine | Q33265642 | ||
| Therapeutic vaccines against IgE-mediated allergies | Q33322920 | ||
| A vaccine against nicotine for smoking cessation: a randomized controlled trial | Q33346321 | ||
| Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines | Q33511064 | ||
| A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses | Q34142943 | ||
| Positive and negative selection of T cells | Q34157557 | ||
| Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid | Q34698382 | ||
| Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study | Q34760214 | ||
| Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. | Q34977290 | ||
| T cell anergy | Q35019694 | ||
| On natural and artificial vaccinations | Q35034062 | ||
| Virus-like particles as a modular system for novel vaccines | Q35059416 | ||
| Thymic selection revisited: how essential is it? | Q35076679 | ||
| TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation | Q35540023 | ||
| Therapeutic vaccination for chronic diseases: a new class of drugs in sight | Q35604228 | ||
| Autoreactivity in human IgG+ memory B cells | Q35729131 | ||
| Antigen-specific memory B cell development | Q36072438 | ||
| Peripheral tolerance of CD8 T lymphocytes | Q36076297 | ||
| Cellular and genetic mechanisms of self tolerance and autoimmunity | Q36148399 | ||
| Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies | Q36167475 | ||
| Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. | Q36228158 | ||
| Igkappa allelic inclusion is a consequence of receptor editing | Q36228958 | ||
| T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles | Q36262265 | ||
| A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease | Q36367445 | ||
| The Cellular Location of Self-antigen Determines the Positive and Negative Selection of Autoreactive B Cells | Q36371832 | ||
| Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy | Q36380506 | ||
| Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells. | Q36381002 | ||
| Central tolerance: good but imperfect | Q36382791 | ||
| Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model | Q36383391 | ||
| Human autoantibody silencing by immunoglobulin light chains | Q36399885 | ||
| Defective B cell tolerance checkpoints in systemic lupus erythematosus | Q36402748 | ||
| Impaired early B cell tolerance in patients with rheumatoid arthritis. | Q36402969 | ||
| A central role for central tolerance | Q36427372 | ||
| Silencing of autoreactive B cells by anergy: a fresh perspective. | Q36450009 | ||
| Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library | Q36730236 | ||
| Virus-like particles: flexible platforms for vaccine development | Q36837144 | ||
| Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells | Q37070256 | ||
| Regulation and pro-inflammatory function of interleukin-17 family cytokines | Q37073323 | ||
| Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus | Q37093490 | ||
| IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model | Q37125180 | ||
| Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance | Q37129429 | ||
| Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids | Q37132869 | ||
| Vaccination with cytokines in autoimmune diseases | Q37165366 | ||
| Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles | Q37184404 | ||
| The molecular signature of CD8+ T cells undergoing deletional tolerance | Q37187520 | ||
| Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens | Q37191759 | ||
| Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. | Q37256978 | ||
| Immunodrugs: therapeutic VLP-based vaccines for chronic diseases | Q37292647 | ||
| The coming of age of virus-like particle vaccines | Q37309265 | ||
| Many cytokines are very useful therapeutic targets in disease | Q37316591 | ||
| Emerging applications of anticytokine vaccines | Q37340457 | ||
| Advances in saponin-based adjuvants | Q37390078 | ||
| Characterization and potential clinical applications of autoantibodies against cytokines | Q37391775 | ||
| Challenges in monoclonal antibody-based therapies | Q37398725 | ||
| T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity | Q37415070 | ||
| Aire | Q37419376 | ||
| Immunology of TLR-independent vaccine adjuvants | Q37506781 | ||
| Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells | Q37585179 | ||
| Current developments with peptide-based human tumor vaccines | Q37601263 | ||
| AIRE in the thymus and beyond | Q37615692 | ||
| TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model | Q38797655 | ||
| Influence of B cell antigen receptor expression level on pathways of B cell tolerance induction | Q39901565 | ||
| Vaccine adjuvants alter TCR-based selection thresholds. | Q40096549 | ||
| Antigen epitope-expressing cytokines for DNA immunization. | Q40454030 | ||
| Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. | Q40490993 | ||
| Tolerance through indifference: autoreactive B cells to the nuclear antigen La show no evidence of tolerance in a transgenic model. | Q40614137 | ||
| Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). | Q40964230 | ||
| Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. | Q41162214 | ||
| Complete but curtailed T-cell response to very low-affinity antigen | Q41902378 | ||
| kappa+lambda+ dual receptor B cells are present in the human peripheral repertoire | Q42043636 | ||
| Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice | Q43655979 | ||
| Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response | Q43986613 | ||
| Progressive surface B cell antigen receptor down-regulation accompanies efficient development of antinuclear antigen B cells to mature, follicular phenotype | Q44714968 | ||
| Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases | Q44743660 | ||
| Identification of adjuvants that enhance the therapeutic antibody response to host IgE. | Q44972579 | ||
| Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis | Q45397328 | ||
| A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis | Q45403808 | ||
| A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity | Q45409539 | ||
| Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses | Q45415101 | ||
| Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults | Q45416013 | ||
| Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles | Q45423180 | ||
| Determinants of autoantibody induction by conjugated papillomavirus virus-like particles | Q45730041 | ||
| How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model | Q45783598 | ||
| Virus-induced autoantibody response to a transgenic viral antigen | Q45851561 | ||
| Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice | Q45854348 | ||
| Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis | Q46652738 | ||
| Induction of autoimmunity by immunization with hapten-modified hen egg lysozyme in hen egg lysozyme-transgenic mice | Q46942447 | ||
| CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. | Q47371453 | ||
| Melanoma vaccines: The problems of local immunosuppression | Q47910484 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 561-574 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Immunotherapy | Q18713038 |
| P1476 | title | Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines | |
| P478 | volume | 2 |
| Q36145575 | Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates |
| Q39271088 | Biomaterial strategies for generating therapeutic immune responses |
| Q39215603 | Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis |
| Q36250237 | Follicular dendritic cells in health and disease |
| Q38685586 | Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells |
| Q99711516 | Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis |
| Q41642900 | Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease |
| Q38120922 | Strategies for active TNF-α vaccination in rheumatoid arthritis treatment |
| Q36978476 | Virus-like particles presenting interleukin-33 molecules: immunization characteristics and potentials of blockingIL-33/ST2 pathway in allergic airway inflammation |
Search more.